Pediatric TB: issues related to current and future treatment options.
Pediatric TB continues to be a neglected disease in many endemic areas where limited resources restrict the focus of treatment to only the most infectious TB cases. However, recognition that children contribute to a significant proportion of the global TB disease burden and suffer severe TB-related morbidity and mortality is growing. The WHO published guidelines on the management of pediatric TB in 2006 and child-friendly drug formulations have been made available to deserving low-income nations via the Global Drug Fund since 2008. Increased awareness and improved drug availability re-emphasized the considerable programmatic barriers that remain and the difficulty of establishing an accurate diagnosis in resource-limited settings. This article provides an overview of current treatment practices, factors that influence the provision of effective TB therapy to children in endemic areas and potential future advances. It includes a brief summary of the relevant literature and presents the authors' personal perspectives on issues related to the treatment of pediatric TB.
Marais
Ben J
BJ
Department of Paediatrics & Child Health, Faculty of Health Sciences, Stellenbosch University, Tygerberg, 7505, South Africa. bjmarais@sun.ac.za
Schaaf
H Simon
HS
Donald
Peter R
PR
D000293:Adolescent; D000995:Antitubercular Agents / Q000600:supply & distribution / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D017410:Practice Guidelines as Topic; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology* / Q000517:prevention & control
D000995:Antitubercular Agents